Fig. 4: Prior flavivirus immunity does not affect the changes in clinical parameters. | Nature Communications

Fig. 4: Prior flavivirus immunity does not affect the changes in clinical parameters.

From: Potential role of heterologous flavivirus immunity in preventing urban transmission of yellow fever virus

Fig. 4: Prior flavivirus immunity does not affect the changes in clinical parameters.

Animal weights (a, b), rectal temperatures (c, d), serum alanine transaminase (ALT) (e, f), and serum aspartate aminotransferase (AST) (g, h) were measured from 1–5 and on 14 DPI and compared to baseline (day 0) values. Data were analyzed by two-way ANOVA with Dunnett’s multiple comparison test. The means of groups DENV-2 P8-immune (n = 8), DENV-2 NGC-immune (n = 3), DENV-2 SN (n = 2), ZIKV PR-immune (n = 3), and ZIKV DakAr-immune (n = 3) were compared with the flavivirus-naïve, i.e., control group (n = 3) at each time point. Flavivirus-naïve group had significantly higher AST levels compared to DENV-2 NGC-immune group (p = 0.0092) at 2DPI, and DENV-2 P8-immune group (p = 0.0043) at 3DPI. Data are presented as mean values ± SD. Statistical significance (*) color is attributed to the significant difference between that group compared to the flavivirus-naïve group. Source data are provided as a Source Data file.

Back to article page